Susquehanna Fundamental Investments, LLC Sage Therapeutics, Inc. Transaction History
Susquehanna Fundamental Investments, LLC
- $6.94 Billion
- Q1 2025
A detailed history of Susquehanna Fundamental Investments, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 211,563 shares of SAGE stock, worth $1.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
211,563
Previous 215,871
2.0%
Holding current value
$1.5 Million
Previous $1.17 Million
43.43%
% of portfolio
0.02%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
51.5MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$36.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$35.9 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$31.7 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$19.3 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$14.8 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $420M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...